Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies

Gene Therapy

Volumn 11, Issue 14, 2004, Pages 1146-1154

  Rollman, E ^a   Hinkula, J ^a   Arteaga, J ^a   Zuber, B ^a   Kjerrstrom A ^a   Liu, M ^a,b   Wahren, B ^a   Ljungberg, K ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b TRANSGENE S A   (France)

Author keywords

Antibody neutralization; DNA immunization; GM CSF; gp160; HIV 1

Indexed keywords

ALUMINUM HYDROXIDE; DNA VACCINE; EPITOPE; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; OLIGODEOXYNUCLEOTIDE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VIRUS ENVELOPE PROTEIN; IMMUNOGLOBULIN G; VIRUS ANTIBODY;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN RECOGNITION; ARTICLE; CELLULAR IMMUNITY; CLADISTICS; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; FEMALE; GENETIC CODE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PEPTIDE MAPPING; PRIORITY JOURNAL; SERUM; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS STRAIN; ANIMAL; BLOOD; C57BL MOUSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HUMAN; IMMUNOLOGY; METHODOLOGY; T LYMPHOCYTE;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY, ACTIVE; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES; VACCINES, DNA;

EID: 4243109693     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302275     Document Type: Article

References (52)

1. UNAIDS/WHO. AIDS epidemic update: December 2003. UNAIDS/WHO, (www.unaids.org) 2003.
2. Wahren B. HIV in Europe - a growing threat. J Clin Virol 2001; 21: 171-173.
3. Kanki PJ et al. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 1999; 179: 68-73.
4. McMichael AJ, Hanke T. HIV vaccines 1983-2003. Nat Med 2003; 9: 874-880.
5. Nabel GJ. HIV vaccine strategies. Vaccine 2002; 20: 1945-1947.
6. Berman PW VaxGen Announces Results of its Phase III HIV Vaccine Trial in Thailand: Vaccine Fails to Meet Endpoints, http://www.vaxgen.com/pressroom/index.htmlVaxGen Announces Results of its Phase III HIV Vaccine Trial in Thailand: Vaccine Fails to Meet Endpoints, http://www.vaxgen.com/pressroom/index.html> 2003.
7. Hanke T, McMichael AJ. Design and construction of an experimental HIV-1 vaccine for a year - 2000 clinical trial in Kenya. Nat Med 2000; 6: 951-955.
8. Shiver JW et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002; 415: 331-335.
9. Calarota SA et al. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. J Immunol 1999; 163: 2330-2338.
10. Boyer JD et al. Therapeutic immunization of HIV-infected chimpanzees using HIV-1 plasmid antigens and interleukin-12 expressing plasmids. AIDS 2000; 14: 1515-1522.
11. Gaschen B. Diversity considerations in HIV-1 vaccine selection. Science 2003; 299: 1515-1518.
12. Moore JP, Parren PW, Burton DR. Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. J Virol 2001; 75: 5721-5729.
13. Muthumani K ZD et al. Novel engineered HIV-1 East African Clade-A gp160 plasmid construct induces strong humoral and cell-mediated immune responses in vivo. Virology 2003; 15: 134-146.
14. Barouch DH et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphoctes. Nature 2002; 415: 335-339.
15. Barouch DH et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000; 290: 486-492.
16. Barouch DH et al. Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CFE. J Immunol 2002; 168: 562-568.
17. Sin JI et al. IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge. J Immunol 1999; 162: 2912-2921.
18. Sin JI et al. Interleukin 7 can enhance antigen-specific cytotoxic-T-lymphocyte and/or Th2-type immune responses in vivo. Clin Diagn Lab Immunol 2000; 7: 751-758.
19. Kato H et al. Rectal and vaginal immunization with a macromolecular multicomponent peptide vaccine candidate for HIV-1 infection induces HIV-specific protective immune responses. Vaccine 2000; 18: 1151-1160.
20. Kim JJ et al. Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV. J Interferon Cytokine Res 1999; 19: 77-84.
21. Moore AC, Kong WP, Chakrabarti BK, Nabel GJ. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice. J Virol 2002; 76: 243-250.
22. Zuber B et al. Induction of immune responses and break of tolerance by DNA against the HIV-1 coreceptor CCR5 but no protection from SIVsm challenge. Virology 2000; 278: 400-411.
23. Davis HL et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 1998; 160: 870-876.
24. Zuber B, Mäkitalo B, Zuber AK, Wahren B. A novel potent strategy for induction of immunity to HIV-1 reverse transcriptase in primates. AIDS 2002; 16: 1839-1840.
25. Deml L et al. Immunostimulatory CpG motifs trigger a T helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp 160 envelope proteins. Clin Chem Lab Med 1999; 37: 199-204.
26. Halperin SAVNG et al. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 2003; 21: 2461-2467.
27. McCluskie MJ, Weeratna RD, Payette PJ, Davis HL. Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA. FEMS Immunol Med Microbiol 2002; 32: 179-185.
28. Gorny MK et al. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J Virol 2002; 76: 9035-9045.
29. Ljungberg K et al. Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. Virology 2002; 302: 44-57.
30. Chakrabarti BK et al. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J Virol 2002; 76: 5357-5368.
31. Iwasaki A et al. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J Immunol 1997; 158: 4591-4601.
32. Kusakabe K et al. The timing of GM-CSF expression plasmid administration influences the Thl/Th2 response induced by an HIV-1-specific DNA vaccine. J Immunol 2000; 164: 3102-3111.
33. Feltquate DM, Heaney S, Webster RG, Robinson HL. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol 1997; 158: 2278-2284.
34. Guay LA et al. Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda. AIDS 2002; 16: 1391-1400.
35. Poignard P, Saphire EO, Parren PW, Burton DR. gp120: Biologic aspects of structural features. Annu Rev Immunol 2001; 19: 253-274.
36. Wang B et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993; 90: 4156-4160.
37. Klenerman P, Zinkernagel RM. Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature 1998; 394: 482-485.
38. Kundu SK et al. Role of preimmunization virus sequences in cellular immunity in HIV-infected patients during HIV type 1 MN recombinant gp160 immunization. AIDS Res Hum Retroviruses 1998; 14: 1669-1678.
39. Maurer T et al. CpG-DNA aided cross-presentation of soluble antigens by dendritic cells. Eur J Immunol 2002; 32: 2356-2364.
40. Liu HM et al. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Blood 1998; 92: 3730-3736.
41. Ayash-Rashkovsky M et al. Induction of antigen-specific Th1-biased immune responses by plasmid DNA in schistosoma-infected mice with a preexistent dominant Th2 immune profile. Biochem Biophys Res Commun 2001; 282: 1169-1176.
42. Weeratna RD, Brazolot Millan CL, McCluskie MJ, Davis HL. CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice. FEMS Immunol Med Microbiol 2001; 32: 65-71.
43. Wang R et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998; 282: 476-480.
44. Calarota S et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998; 351: 1320-1325.
45. MacGregor RR et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998; 178: 92-100.
46. Kjerrström A et al. Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines. Virology 2001; 284: 46-61.
47. Akerblom L et al. Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120. AIDS 1990; 4: 953-960.
48. Broliden PA et al. Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc Natl Acad Sci USA 1992; 89: 461-465.
49. Calarota S et al. Immunodominant glycoprotein 41 epitope identified by seroreactivity in HIV type 1-infected individuals. AIDS Res Hum Retroviruses 1996; 12: 705-713.
50. Wang JJ, Steel S, Wisniewolski R, Wang CY. Detection of antibodies to human T-lymphotropic virus type III by using a synthetic pepticle of 21 amino acid residues corresponding to a highly antigenic segment of gp4l envelope protein. Proc Natl Acad Sci USA 1986; 83: 6159-6163.
51. Hinkula J et al. Immunological and virological interactions in patients receiving passive immunotherapy with HIV-1 neutralizing monoclonal antibodies. J Acquir Immune Defic Syndr 1994; 7: 940-951.
52. Devito C, Levi M, Broliden K, Hinkula J. Mapping of B-cell epitopes in rabbits immunised with various gag antigens for the production of HIV-1 gag capture ELISA reagents. J Immunol Methods 2000; 238: 69-80.